



Webinar

China's Changing Role in the Global Pharmaceutical System

Implications for National and Global Public Health

Peter Yu and Yuanqiong Hu

29 October 2019

Q&A Session with the Participants

16:27:17

From Kaspars Lunte: Hello, question: what about China's approach for compulsory licensing to ensure access to innovative life-saving medicines, such as for drug-resistant TB? What is the status now and how it will change? Thanks!

16:28:55

From David: How much of this issue in China is driven by industrial/innovation policy versus health interests?

16:28:56

From Haoyi Wang : Question: if China is putting the effort of innovation, does it mean compare to in favour of generics, China is in favour of encouraging innovation drugs development?

16:31:44

From Marcela Vieira : Question: you mentioned that the current push for changes in the IP and data exclusivity is coming from within China, opposed to previous changes that occurred mostly due to pressures from outside of China. Could you please develop more on who are the actors in China pushing for the current changes?

16:32:11

From Luis Gil Abinader: Thank you for this presentation Professor Yu. Could you comment on Chinese policies to increase the number of patents over publicly-funded inventions? To what extent is China trying to implement Bayh-Dole Act-type policies?

16:32:29

From Nigorsulton Muzafarova: could you also advise on the GMP requirements for products manufactured for export and domestic use?

16:33:58

From Reji Joseph : There are two possibilities on why China is proposing a change

in patent law pertaining to pharmaceuticals. One, China is confident that it can enter into innovative drugs (but this does not appear to be so). Two, China wants to reduce the friction with US in IP front. How do you see the proposed changes in patent law of China?

16:34:58

From Mohga Kamal-Yanni: What is the effects (+ve and -ve) of RECEP on A2M in China? Why is China pushing for FTAs anyway?

16:37:01

From Derek Queisser de Stockalper: Do you see new delivery models / business models to reach "last mile" patients or underserved patients?

16:37:35

From Dimitri Eynikel: Thank you for the presentations. What is the relation between companies producing api and innovators in China? Are these the same companies, different companies? How do they compare in economic weight in China?

16:49:07

From Marcela Vieira : Question: if China moves toward producing more innovative medicines, how will that impact the production and global supply of APIs?

17:02:10

From Vitor Ido: Thank you very much!

17:02:11

From Sofya Khlebnikova: thank you'